| Dave Tomey, MD | |
|
304 Turner Mccall Blvd Sw, Rome, GA 30165-5621 | |
| (706) 509-5000 | |
| Not Available |
| Full Name | Dave Tomey |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 30 Years |
| Location | 304 Turner Mccall Blvd Sw, Rome, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407891468 | NPI | - | NPPES |
| 000927913C | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 050276 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Redmond Regional Medical Center | Rome, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Coverage Corp | 3072412592 | 364 |
News Archive
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) and European CE Mark approval of the Angio-Seal Evolution Vascular Closure Device. The approval and global launch was announced at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.
In the August 12 issue of the Journal of the American Medical Association, the study's authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COX-2 enzyme, a characteristic of two-thirds of colorectal cancers.
› Verified 4 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20050411000056 |
News Archive
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) and European CE Mark approval of the Angio-Seal Evolution Vascular Closure Device. The approval and global launch was announced at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.
In the August 12 issue of the Journal of the American Medical Association, the study's authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COX-2 enzyme, a characteristic of two-thirds of colorectal cancers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dave Tomey, MD 420 E 2nd Ave, Suite 103, Rome, GA 30161-3209 Ph: (706) 509-3000 | Dave Tomey, MD 304 Turner Mccall Blvd Sw, Rome, GA 30165-5621 Ph: (706) 509-5000 |
News Archive
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) and European CE Mark approval of the Angio-Seal Evolution Vascular Closure Device. The approval and global launch was announced at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.
In the August 12 issue of the Journal of the American Medical Association, the study's authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COX-2 enzyme, a characteristic of two-thirds of colorectal cancers.
› Verified 4 days ago
Peter Ankrom, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 E 2nd Ave, Suite 103, Rome, GA 30161 Phone: 706-509-3278 Fax: 706-509-4608 | |
Paul Keith Shumpert, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 501 Redmond Rd Nw, Rome, GA 30165 Phone: 706-291-0291 | |
Cassandra Evans, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Redmond Rd Nw, Rome, GA 30165 Phone: 706-291-0291 | |
John Kevin Hardwell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 304 Turner Mccall Blvd Sw, Rome, GA 30165 Phone: 706-509-6122 Fax: 706-509-4608 | |
Horace Lee Cline, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 420 E 2nd Ave, Suite 103, Rome, GA 30161 Phone: 706-509-3278 Fax: 706-509-4608 | |
William Scott Alexander Ii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 304 Turner Mccall Boulevard, Floyd Center For Wound Care And Hyperbarics, Rome, GA 30165 Phone: 706-509-5170 | |
David Wyatt Saunders, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Redmond Rd Nw, Rome, GA 30165 Phone: 706-291-0291 |